Grandes Programas Asociados a H2020 en Salud

Tamaño: px

Comenzar la demostración a partir de la página:

Download "Grandes Programas Asociados a H2020 en Salud"

Bernardo Romero Belmonte
hace 6 años
Vistas:

1 Grandes Programas Asociados a H2020 en Salud Gloria Villar Acevedo Oficina de Proyectos Europeos Subdirección General de Programas Internacionales de Investigación y Relaciones Institucionales CURSO H2020: Oportunidades de financiación para Investigación e Innovación en Salud: Talleres de preparación y gestión de propuestas

2 Dónde encontrar oportunidades de investigación en Salud en Horizon2020? SC1 2

3 IMI-2 3

IMI-2 Joint Technology Initiatives (JTIs) are a means

a limited number of European Technology Platforms

Public-Private Partnership: 1:1 funding, joint

4 IMI-2 Joint Technology Initiatives (JTIs) are a means to implement the Strategic Research Agendas (SRAs) of a limited number of European Technology Platforms (ETPs). Public-Private Partnership: 1:1 funding, joint decision making EU funds to SMEs & academia Industry contribution in-kind Ideas from industry & academia 4

5 Base conceptual de IMI: Los riesgos del desarrollo farmacéutico Vida total de la patente: 20 años 5 años para explotación!

6 EFPIA (European Federation of Pharmaceutical Industries and Associations) H2020: Oportunidades de financiación para Investigación e Innovación en Salud

7 Goals of the IMI2 programme 7

8 The IMI2 proposal life cycle (for a 2-stages evaluation procedure) H2020: Oportunidades de financiación para Investigación e Innovación en Salud

9 La 8ª convocatoria de IMI Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks

10 Topics propuestos para la 10ª convocatoria Apertura posible:19 octubre 2016, Cierre posible: 24 enero 2017 (1ª fase; 17:00:00 CET)

11 11

12 EDCTP-2 The European & Developing Countries Clinical Trials Partnership 12

tuberculosis, la malaria, así como las enfermedades infecciosas desatendidas en áfrica subsahariana centrándose en la

13 EDCTP-2 Objetivo general: Acelerar el desarrollo de nuevos y mejores fármacos, vacunas y microbicidas contra SIDA, la tuberculosis, la malaria, así como las enfermedades infecciosas desatendidas en áfrica subsahariana centrándose en la fase II y III de los ensayos clínicos EDCTP-1: EDCTP-2: Mas de 400 científicos africano formados (55 senior fellowship, 320 masters and Phd) El 70 % de las actividades coordinadas por científicos africanos

14 Cómo funciona EDCTP-2 14

particular relevance for Africa, including Ebola New tools and

15 Que financia EDCTP2? Diseases: HIV/AIDS, TB, Malaria, NIDs, emerging infectious diseases of particular relevance for Africa, including Ebola New tools and interventions: Diagnostics, drugs, vaccines and microbicides Capacity Development: Fellowships, Networks, Ethics, Regulatory 15

Cameroon, Burkina Faso, Rep of Congo, Ghana, Mali, Mozambique, Niger, Senegal, South Africa, Tanzania, The Gambia,

16 EDCEDCTP2 incluye: TP EDCTP2 Participating States (PSs) 13 European Countries Austria, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain and United Kingdom 13 African Countries Cameroon, Burkina Faso, Rep of Congo, Ghana, Mali, Mozambique, Niger, Senegal, South Africa, Tanzania, The Gambia, Uganda, Zambia Countries that can receive funding All sub-saharan African countries All EU MSs and Associated Countries

EDCTP1 in a nutshell (2003-2014) Number of calls 65 Number of grants awarded 254 Participating countries Sub-Saharan African 30 European 16 (involving 259

17 EDCTP1 in a nutshell ( ) Number of calls 65 Number of grants awarded 254 Participating countries Sub-Saharan African 30 European 16 (involving 259 institutions posts supported) African leadership 72% PhD/MSc trained >400 Senior & Career Fellowships 56 Clinical trials 100 Ethics grants 75 Publications (so far)

18 18

19 AAL-2 ACTIVE ASSISTED LIVING PROGRAMME ICT for ageing well 19

Active Assisted Living- (AAL-2) It is the second phase of a European funding program (2014-2020) based on Art.

185: Article 185 of the Treaty on the Functioning of the European Union (TFEU) [ex Article 169 of the Treaty establishing the European Community (TEC)] enables the EU to

20 Active Assisted Living- (AAL-2) It is the second phase of a European funding program ( ) based on Art. 185 of the Treaty on the Functioning of the European Union (TFEU) Art.185: Article 185 of the Treaty on the Functioning of the European Union (TFEU) [ex Article 169 of the Treaty establishing the European Community (TEC)] enables the EU to participate in research programmes undertaken jointly by several Member States, including participation in the structures created for the execution of national programmes. Driven by the Member States Approved by co-decision program (Council and Parliament) With financial contribution from the European Commission 50% (co-financing). Annual joint calls

AAL-2: programme Objective An overall objective of the AAL

people and strengthen the industrial base in Europe through

21 AAL-2: programme Objective An overall objective of the AAL R&D Programme is to enhance the quality of life of older people and strengthen the industrial base in Europe through the use of Information and Communication Technologies (ICT) tools systems and services. Therefore.. TO BRING INNOVATIVE DIGITAL PRODUCTS AND SERVICES TO THE EUROPEAN MARKET FOR AGING WELL

22 Total funding ( ) ~ 600 M, ~ 50 % public funding (~ half by Partner States and ~ half by EU), ~ 50 % private funding. Project Business Plan: Expected time to market after project completion < 3 years. Call 1: Chronic Conditions Call 3: Self-Serve Society Call 5: Home Care Call 2: Social Interaction ~ 150 projects funded (calls 1 5), SME particiption increased from 38% to 47% and end user varied 16-21% (calls 1 6) Call 6: Occupation in Life Call 4: Mobility

Work Programme AAL-2 Aligned with the priorities of partner countries Defined through cooperation between partner countries, the EC and relevant stakeholders (users) Aligned

23 Work Programme AAL-2 Aligned with the priorities of partner countries Defined through cooperation between partner countries, the EC and relevant stakeholders (users) Aligned with the European Innovation Partnership on Active and Healthy Ageing (EIP AHA), which could further boost the deployment at European level Budget: 700 million over 7 years.

Central Eligibility Criteria Submission of a complete proposal, in English, through the AAL electronic submission system before the deadline Consortium composition: min.

24 Central Eligibility Criteria Submission of a complete proposal, in English, through the AAL electronic submission system before the deadline Consortium composition: min. 3 independent eligible organizations (1 coordinator), from min. 3 different AAL Partner States participating in the Call. Consortium must include at least one eligible: end-user organization business partner SME partner (which can be the business partner) Size of the consortium: 3 10 partners Duration of the project: months Adherence to the specifications for structure and technical details (e.g. page count) given by the proposal submission system.

Características de los proyectos Aims at ICT-based solutions to identified user needs Time-to-market perspective of 2 to 3 years after end project Project total budget: 1-7 M Maximum funding from the

25 Características de los proyectos Aims at ICT-based solutions to identified user needs Time-to-market perspective of 2 to 3 years after end project Project total budget: 1-7 M Maximum funding from the AAL JP: 3 M. Significant involvement ( 50%), of industry and business partners, particularly SMEs. Realistic pilot as integrated parts of the project Proactive end-user involvement throughout the project Defined market segment(s), use cases and target group(s) and address the wishes/needs of these specific group(s).

26 Más información 26

27 27

28 ERA.Nets JPIs 28

29 29

30 ERA-Nets: Características Envío de propuesta única conjunta del consorcio europeo. Presupuesto Horizon2020. Cada socio depende de las reglas de su agencia financiadora (e.g. MINECO, ISCIII). La financiación, seguimiento administrativo y justificación depende del financiador (e.g. MINECO, ISCIII). Seguimiento científico es central. El ISCIII participa en 8 ERA-Nets Cofund (TRANSCAN 2, E-RARE 3, ERACoSysMeD, CVD, Neuron y JPco-fuND, JPI- EC-AMR y ERA-HDHL) y en 3 ERA-Nets (EuroNanoMeD, ERA-Net LAC e INFECT-ERA).

31 El esquema ERA-Net H2020: Oportunidades de financiación para Investigación e Innovación en Salud

32 32

33 JPIs: Características Actuar (EEMM, PA) de manera conjunta frente a grandes retos sociales. Impulsado y dirigido por los Estados Miembros y Asociados, pero pueden participar países fuera de la UE (ejem. Canadá) Representantes de alto nivel compromiso. Programas estratégicos a largo plazo sostenibles. Estrategia y agenda de investigación común. Principio de geometría variable (voluntario). ISCIII participa en 4 JPIs: AMR (Resistencia Antimicrobiana), MYBL (Cambio Demográfico) y HDHL (Dieta saludable) y JPND (Neurodegeneración y Alzheimer).

35 Acciones complementarias: ISCIII 35

https://www.era-learn.eu/ ERA-Nets: 1. EuroNanoMed (Nanomedicine ) 2. Infect-ERA (Infectious Diseases) 3.

ERACoSysMed (System Medicine) 4. Neuron (Neuroscience and Neur. Dis.) 5. ERA-CVD (Cardiovascular Diseases) 6.

JP ND (Enfermedades Neurodegenerativas) 2. JPI AMR (Resistencia Antimicrobiana) 3.

36 ERA-Nets: 1. EuroNanoMed (Nanomedicine ) 2. Infect-ERA (Infectious Diseases) 3. ERA-Net LAC ERA-Nets Co-fund: 1. E-RARE (Rare Diseases) 2. TRANSCAN (Translational Cancer) 3. ERACoSysMed (System Medicine) 4. Neuron (Neuroscience and Neur. Dis.) 5. ERA-CVD (Cardiovascular Diseases) 6. JPco-fuND 7. JPI-EC-AMR 8. ERA-HDHL (Biomarkers for Nutrition and Health (BioNH) JPIs: 1. JP ND (Enfermedades Neurodegenerativas) 2. JPI AMR (Resistencia Antimicrobiana) 3. JPI HDHL (Dieta saludable) 4. JPI MYBL (Cambio demográfico) Art. 185: 1. AAL2 (Envejecimiento activo asistido) 2. EDCTP2 (Partenariado EU-países en desarrollo para EE.CC.)

37 DG SANTÉ: Directorate General for Health and Food Safety 3er Programa de Salud UE

implementar Programas Comunitarios complejos, lo que permite a la EC centrarse

and Consumers) y antes era Public Health Executive (PHEA).

38 CHAFEA Quienes son? La CHAFEA es una de las 6 Agencias ejecutivas establecidas por la EC para implementar Programas Comunitarios complejos, lo que permite a la EC centrarse en la parte política Anteriormente se llamaba EAHC (Executive Agency for Health and Consumers) y antes era Public Health Executive (PHEA). En 2016 su mandato se extendió para incluir la gestión del Programa de Promoción de productos agrícolas Consumers, Health, Agriculture and Food Executive Agency CHAFEA- 38

39 Organización: quien hace qué NFP_ES: Maria Jose González de Suso_ISCIII 39

40 Programas de Salud de la UE SC1 (H2020) ~ 7000 M 40

Objetivo General del Programa de Salud 2014-2020 Main European Commission instrument to implement the EU health strategy Complementar y apoyar las

41 Objetivo General del Programa de Salud Main European Commission instrument to implement the EU health strategy Complementar y apoyar las políticas de los Estados Miembros y proporcionarles un valor añadido, para mejorar la salud de los ciudadanos de la unión y reducir las desigualdades sanitarias 41

42 Objetivos específicos del Programa de Salud Annual work plans Priority areas Criteria for funding actions 42

Tipos de Ayudas/Financial mechanisms Actions with MS competent authorities (Joint Actions) (invited procedure for direct awarding) Projects (call for proposals grants)

43 Tipos de Ayudas/Financial mechanisms Actions with MS competent authorities (Joint Actions) (invited procedure for direct awarding) Projects (call for proposals grants) Work of NGOs and Networks (call operating grants) Cooperation with International Organisations (direct grants) Studies, evaluations, IT services, etc (public procurement) 43

44 Elegibilidad (co-financiación!!) Only legally established organisations are able to apply non-governmental organisations public sector bodies public administrations, universities higher education establishments 44

45 45

46 /portal/desktop/en/opportunities/ 46

47 Participación española en el 2 Programa de Salud 30 acciones fueron lideradas por al menos una organización española. España ha recibido una cifra total de 11 M de apoyo financiero Las evaluaciones de propuestas de proyectos españolas tienen un valor promedio más alto que la media europea. 47

48 Acción Conjunta: CHRODIS JA H2020: Oportunidades de financiación para Investigación e Innovación en Salud

Documentos relacionados

Otras oportunidades de participación en H2020 para el sector SALUD

Otras oportunidades de participación en H2020 para el sector SALUD Juan E. Riese, PhD MBA SC1 H2020 NCP Oficina de Proyectos Europeos Instituto de Salud Carlos III H2020: Salud, Cambio demográfico y Bienestar